A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”

Wei Seong Toh, Reza Yarani, Samir El Andaloussi, Byong Seung Cho, Chulhee Choi, Randolph Corteling, Antonin De Fougerolles, Mario Gimona, Josephine Herz, Maroun Khoury, Paul D. Robbins, Douglas Williams, Daniel J. Weiss, Eva Rohde, Bernd Giebel*, Sai Kiang Lim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The International Society for Cell & Gene Therapy Scientific Signature Series event “Therapeutic Advances With Native and Engineered Human EVs” took place as part of the International Society for Cell & Gene Therapy 2022 Annual Meeting, held from May 4 to 7, 2022, in San Francisco, California, USA. This was the first signature series event on extracellular vesicles (EVs) and a timely reflection of the growing interest in EVs, including both native and engineered human EVs, for therapeutic applications. The event successfully gathered academic and industrial key opinion leaders to discuss the current state of the art in developing and understanding native and engineered EVs and applying our knowledge toward advancing EV therapeutics. Latest advancements in understanding the mechanisms by which native and engineered EVs exert their therapeutic effects against different diseases in animal models were presented, with some diseases such as psoriasis and osteoarthritis already reaching clinical testing of EVs. The discussion also covered various aspects relevant to advancing the clinical translation of EV therapies, including EV preparation, manufacturing, consistency, site(s) of action, route(s) of administration, and luminal cargo delivery of RNA and other compounds.

Original languageEnglish
JournalCytotherapy
DOIs
StateAccepted/In press - 2023
Externally publishedYes

Bibliographical note

Funding Information:
WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026 ). RY is supported by Lundbeck foundation grant R303-2018-3148 .

Funding Information:
WST and SKL are supported by the Agency for Science, Technology, and Research under its Health and Biomedical Sciences Industry Alignment Fund Pre-positioning (award no. H19H6a0026). RY is supported by Lundbeck foundation grant R303-2018-3148. Conception and design of the study: BG and SKL. Acquisition of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Analysis and interpretation of data: WST, RY, SEIA, BSC, CC, RC, ADF, MG, JH, MK, PDR, DW, DJW and ER. Drafting or revising the manuscript: WST, RY, BG and SKL. All authors have approved the final article.

Publisher Copyright:
© 2023 International Society for Cell & Gene Therapy

Keywords

  • clinical trials
  • exosomes
  • extracellular vesicles
  • mesenchymal stromal cells
  • therapeutic
  • translation

Fingerprint

Dive into the research topics of 'A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”'. Together they form a unique fingerprint.

Cite this